AU2015299032A1 - Peptides useful for treating cancer - Google Patents

Peptides useful for treating cancer Download PDF

Info

Publication number
AU2015299032A1
AU2015299032A1 AU2015299032A AU2015299032A AU2015299032A1 AU 2015299032 A1 AU2015299032 A1 AU 2015299032A1 AU 2015299032 A AU2015299032 A AU 2015299032A AU 2015299032 A AU2015299032 A AU 2015299032A AU 2015299032 A1 AU2015299032 A1 AU 2015299032A1
Authority
AU
Australia
Prior art keywords
pro
compound
arg
seq
hca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015299032A
Other languages
English (en)
Inventor
Hilmar M. Warenius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2015299032A1 publication Critical patent/AU2015299032A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AU2015299032A 2014-08-06 2015-08-05 Peptides useful for treating cancer Abandoned AU2015299032A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1413942.2 2014-08-06
GB1413942.2A GB2530479A (en) 2014-08-06 2014-08-06 Peptides useful for treating cancer
PCT/EP2015/068056 WO2016020437A1 (en) 2014-08-06 2015-08-05 Peptides useful for treating cancer

Publications (1)

Publication Number Publication Date
AU2015299032A1 true AU2015299032A1 (en) 2017-03-23

Family

ID=51587828

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015299032A Abandoned AU2015299032A1 (en) 2014-08-06 2015-08-05 Peptides useful for treating cancer

Country Status (9)

Country Link
US (1) US20170313746A1 (cg-RX-API-DMAC7.html)
EP (1) EP3177716A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017529386A (cg-RX-API-DMAC7.html)
CN (1) CN107406485A (cg-RX-API-DMAC7.html)
AU (1) AU2015299032A1 (cg-RX-API-DMAC7.html)
CA (1) CA2960070A1 (cg-RX-API-DMAC7.html)
GB (1) GB2530479A (cg-RX-API-DMAC7.html)
RU (1) RU2017106945A (cg-RX-API-DMAC7.html)
WO (1) WO2016020437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
GB201602409D0 (en) * 2016-02-10 2016-03-23 Warenius Hilmar M Compositions and uses thereof
GB2582571B (en) 2019-03-25 2024-02-28 Syntherix Ltd Peptides and use thereof
CN113109418B (zh) * 2021-04-21 2022-09-09 苏州大学 一种己糖激酶2抑制剂的筛选方法和小分子化合物在制备抗肿瘤药物中的应用
GB2628421A (en) 2023-03-24 2024-09-25 Syntherix Ltd Peptides and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236569A1 (en) * 2000-12-04 2002-06-18 Sloan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
AU2002316419A1 (en) * 2001-07-05 2003-01-21 Yale University Improvement of viral uptake into cells and tissues
US7439031B2 (en) * 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis
GB0804496D0 (en) * 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
EP2867662B1 (en) * 2012-06-27 2021-01-06 Siscapa Assay Technologies, Inc. Multipurpose mass spectrometric assay panels for peptides
EP3456734B1 (en) * 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules

Also Published As

Publication number Publication date
GB2530479A (en) 2016-03-30
RU2017106945A (ru) 2018-09-06
WO2016020437A1 (en) 2016-02-11
US20170313746A1 (en) 2017-11-02
CN107406485A (zh) 2017-11-28
JP2017529386A (ja) 2017-10-05
GB201413942D0 (en) 2014-09-17
EP3177716A1 (en) 2017-06-14
RU2017106945A3 (cg-RX-API-DMAC7.html) 2019-03-28
CA2960070A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
Mei et al. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2
US20170313746A1 (en) Peptides Useful For Treating Cancer
Mendoza et al. Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
JP2011504462A (ja) 腫瘍の予防および治療のための方法および化合物
Ramos-Molina et al. Cationic cell-penetrating peptides are potent furin inhibitors
D’Amelio et al. The apoptosome: emerging insights and new potential targets for drug design
US20200397894A1 (en) Compositions and methods for treating cancer
CN101384618A (zh) 癌中capcna蛋白-蛋白相互作用的肽基抑制
US20090227521A1 (en) Use of compounds in the treatment of ischemia and neurodegeneration
S Straub Targeting IAPs as an approach to anti-cancer therapy
US11338012B2 (en) BRAF-based polypeptides for treatment of cancer
US7374898B2 (en) Peptide inhibitors against seprase
US12570697B2 (en) Cyclic peptide useful in the treatment of cancer
US20190046600A1 (en) Compositions and uses thereof
MD3969000T2 (ro) Inhibitori de Bcl-2 pentru utilizare în tratamentul unui cancer mediat de Bcl-2 care poartă mutația Gly101Val
Datta Roles of P67/MetAP2 as a tumor suppressor
Pérez‐Payá et al. Molecules that modulate Apaf‐1 activity
CA3001204C (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
US12358867B1 (en) Peptoid-based inhibitors of the protein arginine methyltransferase (PRMT) family
Li Gelatinase inhibitors: a patent review (2011-2017)
Sgorbissa et al. Isopeptidases in anticancer therapy: looking for inhibitors
Chen et al. Further structural optimization and SAR study of sungsanpin derivatives as cell-invasion inhibitors
WO2013178782A1 (en) Allosteric inhibitors of ns3 protease from hepatitis c virus
WO2025191093A1 (en) C-raf inhibitors
WO2024200264A1 (en) Peptides and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application